GlassScriptPhysician profile
Vichin C Puri
NPI 1003060211
$2,131.74
in general payments reported to CMS, 2019-2025
20 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.31 · 2020: $159 · 2021: $680 · 2022: $159 · 2023: $332 · 2024: $161 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.45 | 2019-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $285.15 | 2020-2024 | Ocaliva |
| Histosonics, INC. | $279.32 | 2025 | |
| Abbvie INC. | $240.02 | 2020-2024 | |
| Gilead Sciences, INC. | $187.12 | 2020-2021 | |
| Stryker Corporation | $170.57 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $152.58 | 2025 | Phasix Mesh |
| Eurofins Viracor, LLC | $129.05 | 2021 | |
| Hemosonics LLC | $65.82 | 2023 | Quantra Qplus System |
| Eisai INC. | $45.57 | 2024-2025 | |
| Fujifilm Healthcare Americas Corporation | $27.71 | 2025 | |
| Madrigal Pharmaceuticals | $24.69 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $23.79 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $23.46 | 2023 | Oxlumo |
| Dynavax Technologies Corporation | $19.01 | 2023 | Heplisav-B |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $17.66 | 2019 | |
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Carglumic Acid, Galzin, Betaine Anhydrous |
| Shire North American Group INC | $14.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.84 | 2022 | |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vichin Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.